Sequential BCMA CAR T-cell therapy in refractory multiple myeloma
Multiple myeloma (MM) relapsing after B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell treatment remains a therapeutic challenge. Data on re-exposure to CAR T-cell therapy targeting the same antigen are scarce. We analyzed 10 heavily pretreated patients with RRMM at 3...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
23 September 2025
|
| In: |
Blood advances
Year: 2025, Volume: 9, Issue: 18, Pages: 4624-4630 |
| ISSN: | 2473-9537 |
| DOI: | 10.1182/bloodadvances.2025016712 |
| Online Access: | Verlag, kostenfrei, Volltext: https://doi.org/10.1182/bloodadvances.2025016712 Verlag, kostenfrei, Volltext: https://www.sciencedirect.com/science/article/pii/S2473952925003945 
|
| Author Notes: | Tim Richardson, Udo Holtick, Jan-Hendrik Frenking, Hishan Tharmaseelan, Hyatt Balke-Want, Ruth Flümann, Elias Karl Mai, Sandra Sauer, Raphael Teipel, Malte von Bonin, Michael Hallek, Christof Scheid, and Philipp Gödel |
MARC
| LEADER | 00000naa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1949760367 | ||
| 003 | DE-627 | ||
| 005 | 20260120121917.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 260120s2025 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1182/bloodadvances.2025016712 |2 doi | |
| 035 | |a (DE-627)1949760367 | ||
| 035 | |a (DE-599)KXP1949760367 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Richardson, Tim |d 1990- |e VerfasserIn |0 (DE-588)1169965903 |0 (DE-627)1037040481 |0 (DE-576)512345872 |4 aut | |
| 245 | 1 | 0 | |a Sequential BCMA CAR T-cell therapy in refractory multiple myeloma |c Tim Richardson, Udo Holtick, Jan-Hendrik Frenking, Hishan Tharmaseelan, Hyatt Balke-Want, Ruth Flümann, Elias Karl Mai, Sandra Sauer, Raphael Teipel, Malte von Bonin, Michael Hallek, Christof Scheid, and Philipp Gödel |
| 264 | 1 | |c 23 September 2025 | |
| 300 | |b Diagramme | ||
| 300 | |a 7 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Online verfügbar 15 July 2025, Version des Artikels 13 September 2025 | ||
| 500 | |a Gesehen am 20.01.2026 | ||
| 520 | |a Multiple myeloma (MM) relapsing after B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell treatment remains a therapeutic challenge. Data on re-exposure to CAR T-cell therapy targeting the same antigen are scarce. We analyzed 10 heavily pretreated patients with RRMM at 3 medical centers treated with the commercially approved CAR T-cell therapy product idecabtagene vicleucel in a real-world setting. Upon relapse, all patients received ciltacabtagene autoleucel as a second CAR T-cell therapy infusion, with bridging treatments permitted between both therapies. Sequential therapy with BCMA-directed CAR T-cell therapy was safe, with no higher-grade immune-cell-associated side effects or new safety signals. We found robust CAR T-cell therapy expansion and high response rates (100% with at least very good partial response, with 60% achieving minimal residual disease negativity), with an estimated progression-free survival of 64.8% (95% confidence interval, 39%-100%) at 6 months after the second CAR T-cell treatment. Duration of response to first CAR T-cell therapy was predictive for durable responses to the second CAR T-cell therapy product. Loss of BCMA antigen occurred in only 1 of 3 patients relapsing after ciltacabtagene autoleucel. Two of three relapsing patients died within a year, and showed no further response to bispecific antibody treatment. To our knowledge, this study provides the first real-world evidence that sequential treatment with 2 different commercially approved BCMA CAR T-cell therapy products is both feasible and effective, particularly in patients with prolonged responses to initial BCMA CAR T-cell therapy. | ||
| 700 | 1 | |a Holtick, Udo |e VerfasserIn |4 aut | |
| 700 | 1 | |a Frenking, Jan |e VerfasserIn |0 (DE-588)1181399858 |0 (DE-627)1662669607 |4 aut | |
| 700 | 1 | |a Tharmaseelan, Hishan |e VerfasserIn |4 aut | |
| 700 | 1 | |a Balke-Want, Hyatt |e VerfasserIn |4 aut | |
| 700 | 1 | |a Flümann, Ruth |e VerfasserIn |4 aut | |
| 700 | 1 | |a Mai, Elias K. |d 1985- |e VerfasserIn |0 (DE-588)1049182545 |0 (DE-627)781300274 |0 (DE-576)403130999 |4 aut | |
| 700 | 1 | |a Sauer, Sandra |d 1975- |e VerfasserIn |0 (DE-588)1060031140 |0 (DE-627)799171778 |0 (DE-576)416132855 |4 aut | |
| 700 | 1 | |a Teipel, Raphael |e VerfasserIn |4 aut | |
| 700 | 1 | |a von Bonin, Malte |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hallek, Michael |e VerfasserIn |4 aut | |
| 700 | 1 | |a Scheid, Christof |e VerfasserIn |4 aut | |
| 700 | 1 | |a Gödel, Philipp |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Blood advances |d Washington, DC : American Society of Hematology, 2016 |g 9(2025), 18 vom: Sept., Seite 4624-4630 |h Online-Ressource |w (DE-627)873588312 |w (DE-600)2876449-3 |w (DE-576)48043249X |x 2473-9537 |7 nnas |a Sequential BCMA CAR T-cell therapy in refractory multiple myeloma |
| 773 | 1 | 8 | |g volume:9 |g year:2025 |g number:18 |g month:09 |g pages:4624-4630 |g extent:7 |a Sequential BCMA CAR T-cell therapy in refractory multiple myeloma |
| 856 | 4 | 0 | |u https://doi.org/10.1182/bloodadvances.2025016712 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |7 0 |
| 856 | 4 | 0 | |u https://www.sciencedirect.com/science/article/pii/S2473952925003945 |x Verlag |z kostenfrei |3 Volltext |7 0 |
| 951 | |a AR | ||
| 992 | |a 20260120 | ||
| 993 | |a Article | ||
| 994 | |a 2025 | ||
| 998 | |g 1060031140 |a Sauer, Sandra |m 1060031140:Sauer, Sandra |d 910000 |d 910100 |e 910000PS1060031140 |e 910100PS1060031140 |k 0/910000/ |k 1/910000/910100/ |p 8 | ||
| 998 | |g 1049182545 |a Mai, Elias K. |m 1049182545:Mai, Elias K. |d 910000 |d 910100 |d 50000 |e 910000PM1049182545 |e 910100PM1049182545 |e 50000PM1049182545 |k 0/910000/ |k 1/910000/910100/ |k 0/50000/ |p 7 | ||
| 998 | |g 1181399858 |a Frenking, Jan |m 1181399858:Frenking, Jan |d 910000 |d 910100 |e 910000PF1181399858 |e 910100PF1181399858 |k 0/910000/ |k 1/910000/910100/ |p 3 | ||
| 999 | |a KXP-PPN1949760367 |e 4855138258 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"person":[{"family":"Richardson","given":"Tim","role":"aut","display":"Richardson, Tim"},{"family":"Holtick","display":"Holtick, Udo","role":"aut","given":"Udo"},{"family":"Frenking","role":"aut","given":"Jan","display":"Frenking, Jan"},{"family":"Tharmaseelan","given":"Hishan","role":"aut","display":"Tharmaseelan, Hishan"},{"family":"Balke-Want","display":"Balke-Want, Hyatt","role":"aut","given":"Hyatt"},{"family":"Flümann","role":"aut","given":"Ruth","display":"Flümann, Ruth"},{"family":"Mai","role":"aut","given":"Elias K.","display":"Mai, Elias K."},{"family":"Sauer","display":"Sauer, Sandra","given":"Sandra","role":"aut"},{"display":"Teipel, Raphael","role":"aut","given":"Raphael","family":"Teipel"},{"family":"von Bonin","display":"von Bonin, Malte","role":"aut","given":"Malte"},{"role":"aut","given":"Michael","display":"Hallek, Michael","family":"Hallek"},{"display":"Scheid, Christof","given":"Christof","role":"aut","family":"Scheid"},{"given":"Philipp","role":"aut","display":"Gödel, Philipp","family":"Gödel"}],"name":{"displayForm":["Tim Richardson, Udo Holtick, Jan-Hendrik Frenking, Hishan Tharmaseelan, Hyatt Balke-Want, Ruth Flümann, Elias Karl Mai, Sandra Sauer, Raphael Teipel, Malte von Bonin, Michael Hallek, Christof Scheid, and Philipp Gödel"]},"note":["Online verfügbar 15 July 2025, Version des Artikels 13 September 2025","Gesehen am 20.01.2026"],"relHost":[{"part":{"text":"9(2025), 18 vom: Sept., Seite 4624-4630","year":"2025","volume":"9","extent":"7","pages":"4624-4630","issue":"18"},"language":["eng"],"title":[{"title":"Blood advances","title_sort":"Blood advances"}],"pubHistory":["Vol. 1, iss. 1 (November 2016)-"],"name":{"displayForm":["American Society of Hematology"]},"note":["Gesehen am 27.04.21"],"disp":"Sequential BCMA CAR T-cell therapy in refractory multiple myelomaBlood advances","physDesc":[{"extent":"Online-Ressource"}],"id":{"eki":["873588312"],"issn":["2473-9537"],"zdb":["2876449-3"]},"type":{"media":"Online-Ressource","bibl":"periodical"},"recId":"873588312","origin":[{"publisher":"American Society of Hematology","dateIssuedDisp":"[2016]-","publisherPlace":"Washington, DC"}]}],"physDesc":[{"extent":"7 S.","noteIll":"Diagramme"}],"id":{"eki":["1949760367"],"doi":["10.1182/bloodadvances.2025016712"]},"recId":"1949760367","origin":[{"dateIssuedKey":"2025","dateIssuedDisp":"23 September 2025"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"language":["eng"],"title":[{"title":"Sequential BCMA CAR T-cell therapy in refractory multiple myeloma","title_sort":"Sequential BCMA CAR T-cell therapy in refractory multiple myeloma"}]} | ||
| SRT | |a RICHARDSONSEQUENTIAL2320 | ||